---
run_id: halo-evidence-vs-diagnosis-validation-v12-generic-advice-prompted-03
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: generic_advice_prompted
run_number: 3
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 305
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 2d3cd0a66ac65ac18e241525d58fddd7447998bf4d887a6f8c7bfef16372a25d
condition_packet_sha256: 2d3cd0a66ac65ac18e241525d58fddd7447998bf4d887a6f8c7bfef16372a25d
output_file: model-outputs/generic_advice_prompted-03.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 03)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `generic_advice_prompted`, run 3 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 305, on the frozen condition packet.

## Output

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Tradeoffs

You are currently facing a classic "false positive" signal. Your executive team sees growth (expansion bookings, shortened cycles) and attributes it to product-market fit. However, the granular data suggests this growth is driven by **sales incentives** (bundle pricing) and **buyer aspiration** (the roadmap pitch), rather than **user utility**.

The risk is that you are scaling a "leaky bucket." The evidence of analysts falling back to manual notes, the inability of public-sector users to explain recommendations, and the quiet churn in regional accounts indicate that PlanPilot is currently a "management tool" (used for enablement and reviews) rather than a "workflow tool" (integrated into the analyst's daily habit).

Here is why the other options are insufficient or dangerous:
*   **Scale PlanPilot Broadly:** This is high-risk. If the core utility is missing, scaling will only accelerate churn once the "bundle price" honeymoon ends.
*   **Adoption Quality Sprint:** This measures *what* is happening (event tracking) but not *why*. You already know the usage patterns are skewed toward managers; more dashboards won't tell you why analysts abandon the tool.
*   **Demand Cleanroom:** This tests sales elasticity, not product value. It tells you if the product is sellable without discounts, but it doesn't tell you how to fix the product so that users actually keep it.
*   **Narrow to Public Sector:** This is premature. The public sector has specific "explainability" hurdles, but you don't yet know if the core engine is failing across all segments or just that specific one.

The **Case Evidence Review** is the only option that addresses the "truth gap." By auditing actual case files, you move from *proxy metrics* (usage pings) to *outcome metrics* (accepted vs. overridden suggestions). This reveals whether the "strong quarter" was a result of a great product or a great sales motion.

### The Recommendation
**Commit to the Case Evidence Review.** Use the next twelve days to define the sample set and the rubric for "accepted/overridden/impossible." This provides the empirical basis to decide—mid-year—whether to pivot the roadmap or double down on scaling.

### The Strongest Reason Against It
The Case Evidence Review is slow, manual, and "un-sexy" compared to the growth metrics the board currently loves. By choosing this, you are effectively telling the CEO and Board: *"The recent growth might be an illusion."* This risks damaging the current momentum and political capital the product team has gained by being seen as "commercially disciplined." You are trading a high-growth narrative for an uncomfortable truth.

### Observable Evidence That Would Change My Mind
I would switch my recommendation to **Scale PlanPilot Broadly** if you can produce evidence that the "manual notes" fallback is not a failure of the tool, but a requirement of the industry's compliance standards.

Specifically: if you find that analysts *do* accept PlanPilot’s recommendations but are *required* to transcribe them into manual notes for legal auditing purposes, then the product is already providing value—it just needs a "export to audit log" feature. In that case, the utility is proven, and you should scale immediately.
